$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Tucatinib/Tucatinib is a targeted drug or chemotherapy drug
2026-02-01 22:25:32
Check Details
Alpelisib plus fulvestrant meets primary PFS endpoint in CDK4/6 inhibitor-pretreated patients with PIK3CA mutant HR+/HER2 breast cancer
2026-02-01 22:25:32
Check Details
Which is better, fostatinib/fotantinib or eltrombopag?
2026-02-01 22:25:32
Check Details
Treatment and relief methods for side effects of Serputinib/Serpatinib (Ruitu)
2026-02-01 22:25:32
Check Details
FDA grants accelerated approval to Voyxact (sibprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy
2026-02-01 22:25:32
Check Details
KEYNOTE-775 confirms broad efficacy of lenvatinib plus pembrolizumab in advanced endometrial cancer
2026-02-01 22:25:32
Check Details
Is Belumosudil tablets currently on the market? What is the sales situation?
2026-02-01 22:25:32
Check Details
A comprehensive analysis of the precautions for using Brivaracetam
2026-02-01 22:25:32
Check Details
What is the relevant marketing information about fezolinetant?
2026-02-01 22:25:32
Check Details
What are the indications for Obeticholic acid?
2026-02-01 22:25:32
Check Details
What are the possible adverse reactions of Obeticholic acid?
2026-02-01 22:25:32
Check Details
Deuterated colexitinib (decavatinib) is most effective when taken before or after meals
2026-02-01 22:25:32
Check Details
1
2
...
2325
2326
2327
2328
2329
2330
2331
...
2440
2441
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
FDA Approves Daraxonrasib, Marking Milestone in Metastatic Pancreatic Cancer Treatment
2
FDA Approves Zanidatamab (Ziihera): HER2 Bispecific Antibody Plus Immunotherapy for First-Line Gastric Cancer
3
Neurokinin Receptor Antagonists: A Non-Hormonal Approach to Menopausal Hot Flashes and Sleep Disturbances
4
FDA Approves Tauklarify for Tau PET Imaging in Alzheimer's Disease Assessment
5
First CELMoD Drug Zenbexus Wins FDA Accelerated Approval for Multiple Myeloma
6
FDA Approves First mRNA Flu Vaccine mFLUSIVA
7
FDA Approves Orzeyful, the World's First Orexin Receptor Agonist for Narcolepsy Type 1, Ushering in a New Era of Root-Cause Therapy
8
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
9
AbbVie’s TEPKINLY (epcoritamab) Plus R² Granted EU Approval for Relapsed/Refractory Follicular Lymphoma
10
Global Oncology Update: Breakthroughs in Advanced Cancer Survival and Novel Therapies
11
Phase 1 Study Progress of Ceralasertib in Combination with Durvalumab for Advanced NSCLC and HNSCC
12
Global Breakthroughs in Cancer Drugs and Advanced Treatment Technologies